Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Emmaus Life Sciences Inc (EMMA)

Emmaus Life Sciences Inc (EMMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,081
  • Shares Outstanding, K 70,188
  • Annual Sales, $ 16,650 K
  • Annual Income, $ -6,450 K
  • EBIT $ -1 M
  • EBITDA $ 0 M
  • 60-Month Beta 9.38
  • Price/Sales 0.09
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.12
  • Most Recent Earnings $-0.03 on 11/14/25
  • Next Earnings Date 04/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0130 +18.46%
on 01/16/26
0.0155 -0.65%
on 02/09/26
+0.0024 (+18.46%)
since 01/07/26
3-Month
0.0090 +71.11%
on 11/17/25
0.0155 -0.65%
on 02/09/26
+0.0020 (+14.93%)
since 11/07/25
52-Week
0.0080 +92.50%
on 10/20/25
0.0470 -67.23%
on 02/18/25
-0.0146 (-48.67%)
since 02/05/25

Most Recent Stories

More News
Emmaus Life Sciences Announces Strategic Transaction

Enters into North American License and Exclusive Distribution Agreement

EMMA : 0.0154 (+10.79%)
Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif. , Nov. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...

EMMA : 0.0154 (+10.79%)
Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif. , Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...

EMMA : 0.0154 (+10.79%)
The Leading Emerging Markets For Market-Beating Gains in 2024

Emerging markets are expected to outperform over the next year and will be led by countries like Brazil and India, if for different reasons.

INCO : 65.06 (+0.29%)
EWW : 80.31 (-0.21%)
EWZ : 39.02 (+1.83%)
EEM : 61.24 (+1.06%)
VALE : 17.21 (+2.81%)
EMMA : 0.0154 (+10.79%)
SPY : 693.55 (+0.21%)
EPI : 46.35 (-0.32%)
PSMT : 153.66 (-0.54%)
Emmaus Life Sciences Reports Management Changes

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.0154 (+10.79%)
Emmaus Life Sciences Reports Q2 2023 Financial Results

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.0154 (+10.79%)
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing...

EMMA : 0.0154 (+10.79%)
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine...

EMMA : 0.0154 (+10.79%)
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.0154 (+10.79%)
Emmaus Life Sciences Provides Interim Shipment Data

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended...

EMMA : 0.0154 (+10.79%)

Business Summary

Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States....

See More

Key Turning Points

3rd Resistance Point 0.0166
2nd Resistance Point 0.0161
1st Resistance Point 0.0157
Last Price 0.0154
1st Support Level 0.0148
2nd Support Level 0.0143
3rd Support Level 0.0139

See More

52-Week High 0.0470
Fibonacci 61.8% 0.0321
Fibonacci 50% 0.0275
Fibonacci 38.2% 0.0229
Last Price 0.0154
52-Week Low 0.0080

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar